IncobotulinumtoxinA (Xeomin)

Xeomin (incobotulinumtoxinA) is covered only for the four FDA‑approved adult indications—upper limb spasticity, cervical dystonia, blepharospasm, and chronic sialorrhea—and is excluded for all other indications and for patients <18 years. Approval is limited to adults ≥18 with indication‑specific maximum doses and minimum intervals (blepharospasm ≤100 U total, q≥12 weeks; cervical dystonia ≤120 U, q≥12 weeks; upper limb spasticity ≤400 U, q≥12 weeks; chronic sialorrhea ≤100 U total, q≥16 weeks), approvals last 12 months, and the medical record should document age, diagnosis, dose/site, and prior administration dates.

"Upper limb spasticity (FDA-approved indication) in adults"

Sign up to see full coverage criteria, indications, and limitations.